This antibody reacts specifically with sialyl Lewisa and recognizes an epitope being designated CA 19-9. It does not cross-reacts with Lewisa and Lewisb. CA 19-9 has been shown to be useful marker in the diagnosis and management of gastrointestinal cancers.
